HOME - adaptate

About Adaptate

We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.

UNIQUE BIOLOGY

Our antibodies target gamma delta T cells, a unique class of lymphocytes capable of combining the speed of innate immunity with the selectivity of adaptive immune response.

Gamma delta T cells are located throughout the blood and tissues of the body where they perform a crucial immunosurveillance role, recognising and eradicating stressed and malignant ‘self’. Unlike conventional T-cells, tissue-resident gamma delta T cells are primed for the hypoxic, low nutrient solid tumour environment and form a large proportion of tumour infiltrating lymphocytes (TILs) in a wide variety of cancers.

VIEW TECHNOLOGY

EXQUISITE SELECTIVITY

Our antibodies selectively target only gamma delta T cells thereby offering the opportunity for superior efficacy and safety over and above conventional immunomodulatory therapies such as pan T cell activators.

BROAD POTENTIAL

Gamma delta T cells recognise malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than any one specific antigen.

This is an advantage for both specificity and maintenance of an efficacy response in a wide variety of cancers.

VIEW TECHNOLOGY

INVESTORS

Adaptate Biotherapeutics spun-out from GammaDelta Therapeutics in late 2019.

Adaptate Biotherapeutics has received investment from Abingworth LLP and Takeda Pharmaceutical Company Limited.

Adaptate Biotherapeutics has also benefited from the support of King’s College London, the Francis Crick Institute and Cancer Research Technology.

VIEW TECHNOLOGY

OUR TEAM

We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.

NATALIE MOUNT, PHD

Chief Executive Officer

Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles.

PETER GOODFELLOW, DPHIL

Chair of the Board

Peter was previously the Balfour Professor of Genetics at the University of Cambridge before working for SmithKline Beecham (later GSK) as Head of Research.